Can you provide the upcoming earnings date for CAN FITE BIOPHARMA LTD-ADR?
CAN FITE BIOPHARMA LTD-ADR (CANF) will report earnings on 2026-04-12, before the market open.
CAN FITE BIOPHARMA LTD-ADR (CANF) Forecast, Price Target & Analyst Ratings
NYSEARCA:CANF • US13471N3008
Current stock price
2.92 USD
-0.01 (-0.34%)
At close:
2.92 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CAN FITE BIOPHARMA LTD-ADR (CANF).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.92 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
CANF was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CANF.
In the previous month the buy percentage consensus was at a similar level.
CANF was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-17 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-29 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-31 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | EF Hutton | Maintains | Buy -> Buy |
| 2024-09-24 | EF Hutton | Maintains | Buy -> Buy |
| 2024-08-30 | EF Hutton | Maintains | Buy -> Buy |
| 2024-07-17 | EF Hutton | Initiate | Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-02 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-13 | HC Wainwright & Co. | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 12, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 810K -5.04% | 743K -8.27% | 674K -9.29% | 3.786M 461.72% | 10.998B 290,391.28% | 22.113B 101.06% | 40.102B 81.35% | |
| EBITDA YoY % growth | -10.082M 21.41% | -8.18M 18.87% | -8.123M 0.70% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.096M 21.38% | -8.195M 18.83% | -8.13M 0.79% | -40.886M -402.90% | -337.889M -726.42% | 12.88B 3,911.90% | N/A | |
| Operating Margin | -1,246.42% | -1,102.96% | -1,206.23% | -1,079.92% | -3.07% | 58.25% | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 99.97% | -3.61 13.95% | 0.00 100.00% | 0.00 | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.99%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1,700.90%
Revenue Next 5 Year
914.49%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CAN FITE BIOPHARMA LTD-ADR / CANF Forecast FAQ
What is the expected long term growth rate for CANF stock?
The expected long term growth rate for CAN FITE BIOPHARMA LTD-ADR (CANF) is 1700.9%.